What is Huma?
Huma operates at the intersection of artificial intelligence and clinical care, providing a comprehensive suite of cloud-based platforms designed to modernize healthcare delivery. The company's core offerings facilitate remote patient monitoring, accelerate clinical research, and enable virtual care models that are essential for contemporary health systems. By integrating data-driven decision-making tools, Huma empowers hospitals and life sciences organizations to optimize operational efficiency while simultaneously improving patient outcomes. Its platform serves as a foundational layer for digital transformation, bridging the gap between complex medical data and actionable clinical insights on a global scale.
How much funding has Huma raised?
Huma has raised a total of $296M across 5 funding rounds:
Series A
$28M
Series B
$25M
Series C
$130M
Private Equity
$33M
Series D
$80M
Series A (2018): $28M with participation from NWS Holdings
Series B (2019): $25M led by Bayer
Series C (2021): $130M supported by HAT Technology & Innovation Fund, Hitachi Ventures, Leaps by Bayer, Nikesh Arora, Michael Diekmann, Samsung Next, Unilever Ventures, and Sony Innovation Fund
Private Equity (2022): $33M featuring AstraZeneca
Series D (2024): $80M backed by Hitachi Ventures and AstraZeneca
Key Investors in Huma
Hitachi Ventures
A corporate venture firm that partners with ambitious founders to drive world-changing innovations across digital, industrial, and healthcare sectors.
AstraZeneca
A global pharmaceutical leader focused on the discovery and development of prescription medicines in oncology and biopharmaceuticals.
Bayer
A global enterprise in the life science fields of healthcare and nutrition, dedicated to overcoming challenges presented by a growing and aging global population.
What's next for Huma?
With the successful closure of this major enterprise-level funding, Huma is well-positioned to accelerate its international expansion and deepen its technological capabilities. The strategic backing from industry titans suggests a clear roadmap toward scaling its AI-driven solutions to meet the increasing demand for decentralized and remote care. Moving forward, the company is expected to focus on enhancing its interoperability features and expanding its footprint within the life sciences sector, ensuring that its digital health ecosystem remains at the forefront of medical innovation. This capital injection provides the necessary runway to navigate the complexities of global healthcare regulation while maintaining a competitive edge in the rapidly evolving digital health market.
See full Huma company page
